Oxford Asset Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Oxford Asset Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-921	Closed	-$283K	–	2167
2019 Q3	$283K	Buy	921 +272	+42%	+$88.4K	0.01%	1482
2019 Q2	$207K	Buy	649 +88	+16%	+$30.5K	﹤0.01%	1550
2019 Q1	$235K	Sell	561 -3,020	-84%	-$1.21M	0.01%	1471
2018 Q4	$1.09M	Sell	3,581 -844	-19%	-$273K	0.03%	827
2018 Q3	$1.61M	Buy	4,425 +251	+6%	+$85.9K	0.03%	784
2018 Q2	$1.52M	Buy	+4,174	New	+$1.49M	0.03%	825
2018 Q1	–	Sell	-610	Closed	-$261K	–	1940
2017 Q4	$261K	Buy	610 +157	+35%	+$56.1K	0.01%	1375
2017 Q3	$147K	Buy	+453	New	+$123K	﹤0.01%	1456

Other funds holding EIGR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Oxford Asset Management's EIGR Position: Q4 2019 in Review

Oxford Asset Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2019, closing a stake of 921 shares — an estimated $283K sold.

Oxford Asset Management first reported a position in EIGR in Q3 2017 and held it in 8 quarters. The position peaked at $1.61M in Q3 2018. 91 funds tracked by Wall St. Rank hold EIGR as of Q4 2019.

Oxford Asset Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
Oxford Asset Management sold 921 Eiger BioPharmaceuticals, Inc. shares in Q4 2019, an estimated $283K.
Oxford Asset Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2017 and held it in 8 quarters.
Oxford Asset Management's Eiger BioPharmaceuticals, Inc. position peaked at $1.61M in Q3 2018.
91 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.